Collaboration Agreement

• Expiration Date: 11 February 2015
• Date: 11 February 2012
• Parties: BIOCEPT, INC. (“Biocept”), LIFE TECHNOLOGIES CORPORATION (“Life Technologies”)
• State: California
• Section: Commercial Contracts

Exhibit10.13

COLLABORATIONAGREEMENT

THISCOLLABORATIONAGREEMENT (the“Agreement”)isenteredintoasofNovember2,2012(the“EffectiveDate”)

byandbetweenBIOCEPT,INC.,aCaliforniacorporationhavinganaddressof5810NancyRidgeDrive,Suite150,SanDiego,

CA92121(“Biocept”),andLIFETECHNOLOGIESCORPORATION,aDelawarecorporationhavinganaddressof5791Van

AllenWay,Carlsbad,California92008(“LifeTechnologies”).

WHEREAS,LifeTechnologies,throughitsMedicalSciencesDivision,isengagedinthedevelopmentandcommercialization

ofdiagnosticsystems,testsandlaboratoryservices,includinginoncology;

WHEREAS,Biocepthasdevelopedexpertiseandproprietarytechnologyinenrichment,extractionandanalysisofcirculating

tumorcells(CTCs)foruseinlaboratorydevelopedtestsusedforthenon-invasiveandearlystagedetectionandcharacterization

ofprimary,metastaticorrecurrentcancers;and

WHEREAS,LifeTechnologiesandBioceptdesiretocollaboratesothatBioceptwilldevelopandcommercializeoneor

moreTests,asdefinedherein,forNon-SmallCellLungCancer(NSCLC),usingtheirrespectivetechnologiesandexpertise,on

thetermsandsubjecttotheconditionssetforthherein.LifeTechnologiesandBioceptwillbothpromotethetestandperform

differentcomponentsofthetest,andLifeTechnologieswillprovidetestresultsintheformofreportstophysicians.

NOW,THEREFORE,inconsiderationoftheforegoingpremisesandthemutualcovenantscontainedherein,andintendingto

belegallybound,thepartiesherebyagreeasfollows:



1. DEFINITIONS

1.1“Affiliate”shallmeananycompanyorentitycontrolledby,controlling,orundercommoncontrolwithapartyhereto

andshallincludeanycompanymorethan50%ofwhosevotingstockorparticipatingprofitinterestisownedorcontrolled,directly

orindirectly,byaparty,andanycompanywhichownsorcontrols,directlyorindirectly,morethan50%ofthevotingstockofa

party.

1.2“Assay”shallmeanBiocept’sOncoCEE-LU™(andOncoCEE-LU™withMutationAnalysis)laboratorydeveloped

assayforcharacterizationandprofilingofCTCsfromNSCLCpatients,whichshallincorporate,asPhase1,CTCenumerationby

cytokeratinandCD45(andCEE-Enhanced™whenavailable),EML4/Alk1fusionsandEGFRamplificationbyfluorescencein

situhybridization(determinedbyBiocept);andasPhase2,theadditionaldetectionofmutationsforrelevantgenes,e.g.,K-RAS,

EGFRandB-RAF,asagreedbytheparties,oncapturedCTCsand/orcell-freecirculatingDNA,asagreedbytheparties,and

employingtechnologiesthatpotentiallymayincludeBiocept’sSelectortechnology,andanyimprovementsorenhancements

thereto,exclusiveofnewanalytes(whicharediscussedinSection3.5(f)underCollaborationAssays)orapplicationstoprimary

screening.

1.3“BioceptTrademarks”shallmeanBiocept,Inc.,“OncoCEE-LU ”,“OncoCEE™”,“CEE-Sure ”,CEE-

Enhanced™”,and/orsuchothertrademarksandtradenamesownedorlicensed,andused,byBioceptand/oritsAffiliatesinthe

TerritorytoidentifytheTests,ineachcase,whetherornotregistered.

1.4“LifeTechnologiesTrademarks,”shallmeanLifeTechnologies ,LifeTechnologiesMedicalSciencesand/orsuch

othertrademarksandtradenamesownedorlicensedandusedbyLifeTechnologiestoidentifytheTests,ineachcase,whetheror

notregistered.

1.5“CLIA”shallmeantheClinicalLaboratoryImprovementAmendmentsof1988,asitmaybeamendedfromtimeto

time.

1.6“Collaboration”shallhavethemeaningprovidedSection3.1.

1.7“CollaborationAssay(s)”shallhavethemeaningprovidedinSection3.5(e).

1.8“CPTCode”shallmeantheAmericanMedicalAssociation’s(“AMA”)“CurrentProceduralTerminology”aspublished

intheAMA’sCPTProcessManual,FourthEditionandanysuchfutureeditions,forproceduresusedinperformanceofthe

Assay,andamountsreimbursedbyMedicareforsuchproceduresforlocation99,asmodifiedannually.

1.9“DesignatedExecutiveOfficer”shallmeantheexecutiveofficersofeachpartydesignatedinwritingbeeachpartyas

beingresponsibleforresolvingdisputesrelatedtotheCollaboration,whichshallinitiallybeDavidHaleonbehalfofBioceptand

RonnieAndrewsonbehalfofLifeTechnologies.

1.10“FDA”shallmeantheUnitedStatesFoodandDrugAdministration,oranysuccessorfederalagencythereto.

1.11“HIPAA”shallmean,collectively,theHealthInsurancePortabilityandAccountabilityActof1996,asamended,and

allregulationspromulgatedthereunderat45C.F.R.parts160through164,andtheHealthInformationTechnologyforEconomic

andClinicalHealthActof2009andrelatedregulationsandguidelines.

1.12“IntellectualPropertyRights”meansallnoworhereafterexistingpatents,patentapplications,copyrights,

trademarks(includingservicemarks),tradesecrets,know-how,maskworkrightsanddesignrights,whetherregisteredor

unregistered,andallrightsorformsofprotectionofasimilarnaturehavingequivalentorsimilareffecttoanyoftheforegoing,

whichmaysubsistanywhereintheworld.

1.13“Launch”shallmeanformalcommercialavailabilityandofferingtophysiciansofaTest,asmutuallyagreeduponby

theparties.

1.14“Laws”shallmeanallfederal,stateandlocallawsandregulationsthatapplytothisAgreementincluding,without

limitation,(i)theBayh-DoleAct(ii)the



2

TM TM

TM